The History of Thalidomide

Area of Science:

• Pharmacology
• Teratology
• Drug Safety Regulation

Background:

• Thalidomide (K17) was introduced in 1956, initially lauded for superior sedative effects and perceived safety.
• Reports of adverse effects and a subsequent epidemic of birth deformities emerged shortly after its market launch.
• The thalidomide disaster highlighted critical deficiencies in preclinical drug testing and regulatory oversight.

Purpose of the Study:

• To examine the preclinical testing and regulatory history of thalidomide.
• To assess the role of inadequate animal testing in the thalidomide tragedy.
• To understand the impact of thalidomide's teratogenic effects on drug safety policies.

Main Methods:

• Review of published pharmacological data on thalidomide from 1956.
• Analysis of contemporary accounts and reports concerning drug side effects and fetal abnormalities.
• Examination of preclinical testing protocols and regulatory actions in response to the thalidomide crisis.

Main Results:

• Preclinical safety evaluations for thalidomide were superficial and did not include testing in pregnant animals.
• Thalidomide was withdrawn from the market due to suspected teratogenic effects, later confirmed by animal studies.
• The drug's teratogenicity led to the establishment and strengthening of drug regulatory agencies globally.

Conclusions:

• Inadequate preclinical testing, specifically the absence of teratogenicity studies in pregnant animals, directly contributed to the thalidomide disaster.
• Stricter regulatory frameworks and more rigorous drug safety testing protocols were implemented as a direct consequence of the thalidomide tragedy.
• Enhanced animal testing, particularly in pregnant subjects, is crucial for identifying potential teratogenic risks before drug approval.